Why Cytokinetics, Incorporated (CYTK) Stock Fell 7.5% on Aug 28, 2026
What happened
Cytokinetics fell 5.84% to $73.35 following a sell-the-news reaction to positive Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy announced at the European Society of Cardiology Congress 2026. Despite the clinical win and a raised analyst price target to $81.00 (per Yahoo Finance), the stock experienced profit-taking consolidation intraday.
Watch for stabilization near technical support and monitor Q3 2026 financial results (next earnings scheduled 2026-11-04, consensus EPS estimate –$1.54) for any update on aficamten commercialization timeline or cash runway.
Frequently asked questions
Why did Cytokinetics, Incorporated (CYTK) stock fall on Aug 28, 2026?
Cytokinetics fell 5.84% to $73.35 following a sell-the-news reaction to positive Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy announced at the European Society of Cardiology Congress 2026. Despite the clinical win and a raised analyst price target to $81.00 (per Yahoo Finance), the stock experienced profit-taking consolidation intraday.
How much did CYTK stock fall on Aug 28, 2026?
CYTK fell 7.5% during the Aug 28, 2026 trading session.